Mike Janicek, MD, medical director, Division of Genetics, Arizona Oncology, discusses the use of genetic testing in patients with ovarian cancer.

There has not been enough progress with genetic testing, says Janicek, adding that it has been 2 decades since the discovery of the 

 gene. There has not been enough progress in terms of awareness and application. There are estimates that less than 20% of patients who have had breast and ovarian cancer who are eligible for testing have been tested.

In the oncology world, the numbers are on the rise, but they have yet to reach 100% of where they should be. Despite all of the progress physicians have made, there is still a lot of work that needs to be done. There have, however, been incremental changes in gene panels. There has been progress in terms of therapies, PARP inhibitors, immune therapies, and targeting genetic mutations. This has extended to other fields like and prostate indications, as well.

Videos

Dr. Janicek on Genetic Testing in Patients With Ovarian Cancer

Mike Janicek, MD, medical director, Genetics Division, Arizona Oncology, discusses progress with genetic testing in ovarian cancer.

Janicek says that there has not been enough progress made since the discovery of the 

 gene 2 decades ago. There is not enough awareness about genetic testing, he explains, and less than 20% of patients who are eligible for testing who have breast or ovarian cancer have received it.

Awareness in the oncology space is improving, but there is a long way to go, Janicek says. Incremental changes in ovarian cancer have been made including gene panels, targeted therapies such as PARP inhibitors, and immunotherapy. Genetic testing is now making its way into breast cancer and prostate cancer indications, Janicek concludes.

Mike Janicek, MD, medical director, Genetics Division, Arizona Oncology, discusses progress with genetic testing in ovarian cancer.
 

Mike Janicek, MD

Articles

Dr. Janicek on Genetic Testing in Patients With Ovarian Cancer

Dr. Janicek Discusses Progress in Genetic Testing for Ovarian Cancer